SCHEMBL4067166

SCHEMBL4067166

CC(O)[C@@H]1CCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1841477 1.00
SCHEMBL1841480 1.00
SCHEMBL21022704 1.00
SCHEMBL447351 1.00
SCHEMBL2645499 1.00
SCHEMBL25752110 1.00
SCHEMBL2500151 1.00
Hydrochloric Acid SCHEMBL31603692 0.98
Hydrochloric Acid SCHEMBL17574573 0.98
Hydrochloric Acid SCHEMBL15157492 0.98

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9233926-B2 Compounds for stem cell differentiation SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2016-01-12 US claimed
CN-104684893-A Asymmetric auxiliary group CHIRALGEN LTD 2015-06-03 CN claimed
US-20250250287-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE SWITZERLAND GMBH (CH) 2025-08-07 US disclosed
EP-4568973-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BeiGene Switzerland GmbH (CH) 2025-06-18 EP disclosed
CN-119654327-A Heterocyclic compounds, compositions thereof and methods of treatment thereof 百济神州(苏州)生物科技有限公司 2025-03-18 CN disclosed
US-20240116896-A1 HETEROATOM SUBSTITUTED CYCLIC AND ALKYL AMINES AS ACTIVATORS OF SEROTONIN RECEPTORS ATAI THERAPEUTICS, INC. (US) 2024-04-11 US disclosed
WO-2024032703-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE, LTD. (KY) 2024-02-15 WO disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 EP disclosed
EP-2872147-B1 METHOD FOR MAKING CHIRAL OLIGONUCLEOTIDES WAVE LIFE SCIENCES LTD (SG) 2022-12-21 EP disclosed
EP-3710439-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-09-23 EP disclosed
EP-3458445-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2019-03-27 EP disclosed
EP-2034933-A1 OPHTHALMOLOGICAL COMPOSITION AND USE THEREOF ACRI.TEC AG Gesellschaft Für Ophtalmotologische Productie (DE) 2009-03-18 EP disclosed
WO-2008034598-A1 METHOD FOR THE SYNTHESIS OF HEXAHYDROFURO (2, 3-B) FURAN-3-OL COMPOUNDS DSM IP ASSETS B.V. (NL) 2008-03-27 WO disclosed
WO-2007147599-A1 OPHTHALMOLOGICAL COMPOSITION AND USE THEREOF ACRI.TEC AG GESELLSCHAFT FÜR OPHTALMOTOLOGISCHE PRODUCTE (DE) 2007-12-27 WO disclosed
EP-1594835-A4 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES AUSPEX PHARMACEUTICALS INC (US) 2007-05-02 EP disclosed
EP-1594835-A2 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES Auspex Pharmaceuticals, Inc. (US) 2005-11-16 EP disclosed
US-6800636-B2 FOR THERAPY OF CANCER SCHERING CORPORATION 2004-10-05 US disclosed
WO-2004064745-A2 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES AUSPEX PHARMACEUTICALS, INC. (US) 2004-08-05 WO disclosed
US-20030040520-A1 Farnesyl protein transferase inhibitors GUZI TIMOTHY (US) 2003-02-27 US disclosed
US-6362188-B1 ANTICANCER AGENTS SCHERING CORPORATION 2002-03-26 US disclosed